Supernus Pharmaceuticals Inc (SUPN) Holdings Cut by Sawtooth Solutions LLC

Sawtooth Solutions LLC trimmed its stake in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 39.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 4,595 shares of the specialty pharmaceutical company’s stock after selling 2,966 shares during the quarter. Sawtooth Solutions LLC’s holdings in Supernus Pharmaceuticals were worth $231,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of SUPN. SevenBridge Financial Group LLC purchased a new position in Supernus Pharmaceuticals during the second quarter valued at $113,000. Cubist Systematic Strategies LLC purchased a new position in Supernus Pharmaceuticals during the second quarter valued at $203,000. NumerixS Investment Technologies Inc purchased a new position in Supernus Pharmaceuticals during the second quarter valued at $204,000. Everence Capital Management Inc. purchased a new position in Supernus Pharmaceuticals during the second quarter valued at $205,000. Finally, Cim LLC purchased a new position in Supernus Pharmaceuticals during the second quarter valued at $207,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have issued reports on the stock. BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday. Piper Jaffray Companies set a $47.00 price objective on shares of Supernus Pharmaceuticals and gave the company a “hold” rating in a report on Sunday, July 8th. Cantor Fitzgerald set a $56.00 price objective on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 22nd. ValuEngine raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 19th. Finally, Jefferies Financial Group increased their price objective on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $55.30.

Shares of NASDAQ SUPN opened at $46.51 on Friday. The stock has a market capitalization of $2.48 billion, a PE ratio of 26.57 and a beta of 0.92. The company has a quick ratio of 2.54, a current ratio of 2.74 and a debt-to-equity ratio of 0.82. Supernus Pharmaceuticals Inc has a 52 week low of $33.30 and a 52 week high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.14. The business had revenue of $99.54 million during the quarter, compared to analysts’ expectations of $101.01 million. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. As a group, equities research analysts predict that Supernus Pharmaceuticals Inc will post 1.93 EPS for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Article: Preferred Stock

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply